

#29
goigaPlease type a five digit (-) inside the box ☒

Approved for use through 10/31/2002 PTO/SB/2 (10/02) Q163 0821-0035

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

**REVOCATION OF POWER OF
ATTORNEY OR
AUTHORIZATION OF AGENT**

Application Number	09/280030
Filing Date	MARCH 24, 1999
First Named Inventor	JOHN DUPRE
Group Art Unit	1641
Examiner Name	NOELAN, P.
Attorney Docket Number	4767-180 LAB

I hereby revoke all previous powers of attorney or authorizations of agent given in the above-identified application:

☒ A Power of Attorney or Authorization of Agent is submitted herewith.

OR

☐ Please change the correspondence address for the above-identified application to:☐ Customer Number

OR

Place Customer
Number Bar Code
Label here☐ Firm or
Individual Name

Address

Address

City

State

ZIP

Country

Fax

Telephone

I am the:

☐ Applicant/Inventor☒ Assignee of record of the entire interest. See 37 CFR 3.71
Certificate under 37CFR 3.73(a) is enclosed (Form PTO/SB/96)**SIGNATURE of Applicant or Assignee of Record**

Name

Dr. Joseph Gilbert
Vice President, Research &
Innovation

London Brain Sciences Centre

Signature

Joseph Gilbert

Date

May 26, 2003

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required. See below.

☒ Total of 1 forms are submitted

Read now Statement. This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patent, Washington DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/01 (02-01)

Approved for use through 10/31/2002 OMB 0651-0035
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	09/230,829
Filing Date	March 29, 1999
First Named Inventor	John Dapre
Group Art Unit	1664
Examiner Name	Najaa, F.
Attorney Docket Number	0767-180 LAB

I hereby appoint:

- ☒ Practitioners at Customer Number 24223
OR
☐ Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

- ☐ The above-mentioned Customer Number.

OR

- ☐ Practitioner(s) at Customer Number.

OR

- ☐ Firm or Individual Name

Address

Address

City

Country

Telephone

State

Zip

Fax

I am the:

- ☐ Applicant/Inventor.

- ☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(a) is enclosed. (Form PTO/SB/96).

SIGNATURE of Applicant or Assignee of Record

Name

Dr. Joseph Gilbert
Vice President, Research & Innovation

London Health Sciences Centre

Signature

Date

May 26, 2003

NOTE: Signatures of all the inventors or assignees of record of the entire interest, or their representative(s) are required. Submit multiple

☒ Total of 2 forms are submitted.

This form is estimated to take 3 minutes to complete. Time will vary depending upon the nature of the information entered. Any comments on the form should be sent to the U.S. Patent and Trademark Office, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant: John DupreApplication No. 09/280,020Filed: March 29, 1999Entirety: Treatment of DiabetesLondon Health Sciences Centrea Corporation

(Name of assignor)

(Type of assignor, e.g., Corporation, partnership, university, government agency, etc.)

I state that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of an undivided part interest

in the patent application identified above by virtue of either

- A. ☐ An assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel _____ Frame _____ or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s) of the patent application identified above, to the current assignee as shown below:

1. From _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel: _____ Frame _____ or for which a copy thereof is attached

2. From _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel: _____ Frame _____ or for which a copy thereof is attached

3. From _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel: _____ Frame _____ or for which a copy thereof is attached

☐ Additional documents in the chain of title are listed on a supplemental sheet

☐ Copies of assignments or other documents in the chain of title are attached

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

May 26, 2003

Date

Joseph Gilbert

Signature

Dr. Joseph Gilbert

Typed or printed name

Vice President, Research & Innovation

Title

BURDEN NOW SHIFTS. This form is designed to take 0.2 hours to complete. Time will vary depending upon the needs of the individual. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR ATTORNEY FEES TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ASSIGNMENT

Effective February 21, 2003, and for valuable consideration, we, Amylin Pharmaceuticals, Inc., a corporation organized and existing under and by the virtue of the laws of Delaware and having a place of business at 9373 Towne Centre Drive, San Diego, California 92121, and its successors and assigns; (hereinafter referred to as "Assignors") hereby assign to London Health Sciences Centre, an institution having offices, 375 South Street, London, Ontario N6A 4G5, CANADA, its successors and assigns, (collectively hereinafter called "the Assignee"), the entire right, title and interest throughout the world in the invention and improvements which are the subject of the patents and patent applications listed below, and related applications and patents, any and all United States and foreign patents granted for any of said inventions or improvements, including all divisions, continuations, reissues, continuations-in-part and extensions thereof, and all causes of action for the patents and patent applications listed below, and the right to claim priority based on the filing date of said application and based on the filing date of any provisional application of which said application claims the benefit under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in its own name for patents and like rights of exclusion and for inventor's certificates for said inventions and improvements; and Assignee agrees for ourselves and our legal representatives and assigns, without further compensation, upon request to perform such lawful acts, to promptly provide Assignee with all pertinent facts and documents relating to said invention or application as may be known and accessible to us, to testify in any interference or litigation related to said invention or application and to sign such further applications, assignments, Preliminary Statements and other lawful documents as the Assignee may reasonably request to effectuate fully this Assignment.

Docket No.	Country	Application No. Filing Date	Patent No. Issue/ Grant Date
223/051	U.S.	08/737,446 8 Nov 1996	
241/145	U.S.	09/280,020 29 Mar 1999	
223/051	Europe - Registered in: Austria, Belgium, Switzerland/ Liechtenstein, Germany, Denmark, Spain, France, Great Britain, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, and Sweden	95917874 0 12 May 1995	0762890 26 Jul 2000
223/051	Australia	24044/95 12 May 1995	711611 9 Aug 1999
223/051	Canada	2190112 12 May 1995	
223/051	Japan	529262/1995 12 May 1995	


PATENT

The Assignors hereby covenant that no assignment, sale, agreement, or encumbrance has been or will be made or entered into which would conflict with this Agreement.

WITNESS my hand at San Diego

this 16th Day of April, 2003.

AMYLIN PHARMACEUTICALS, INC.



Lloyd A. Rowland

Vice President and General Counsel

STATE OF California)


) ss

COUNTY OF San Diego)

On April 16, 2003 before me, Cassandra Peters, Notary Public, personally appeared
Lloyd A. Rowland

☒ personally known to me - OR - ☐ proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.



Cassandra Peters
Notary Public in and for said County and State